key: cord-1012035-aw0s0x1u
authors: Tian, Lei; Qiang, Taotao; Liang, Chengyuan; Ren, Xiaodong; Jia, Minyi; Zhang, Jiayun; Li, Jingyi; Wan, Minge; YuWen, Xin; Li, Han; Cao, Wenqiang; Liu, Hong
title: RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic
date: 2021-01-21
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2021.113201
sha: fe400a855581c620146df48b0ea1f0f6b197df28
doc_id: 1012035
cord_uid: aw0s0x1u

The widespread nature of several viruses is greatly credited to their rapidly altering RNA genomes that enable the infection to persist despite challenges presented by host cells. Within the RNA genome of infections is RNA-dependent RNA polymerase (RdRp), which is an essential enzyme that helps in RNA synthesis by catalysing the RNA template-dependent development of phosphodiester bonds. Therefore, RdRp is an important therapeutic target in RNA virus-caused diseases, including SARS-CoV-2. In this review, we describe the promising RdRp inhibitors that have been launched or are currently in clinical studies for the treatment of RNA virus infections. Structurally, nucleoside inhibitors (NIs) bind to the RdRp protein at the enzyme active site, and nonnucleoside inhibitors (NNIs) bind to the RdRp protein at allosteric sites. By reviewing these inhibitors, more precise guidelines for the development of more promising anti-RNA virus drugs should be set, and due to the current health emergency, they will eventually be used for COVID-19 treatment.

Among the major groups of infections, RNA virus infections contribute considerably to the worldwide death and morbidity index related to viral infection.

Chronic illness related to persistent RNA virus infections represents a crucial public health worry [1] . While human immunodeficiency virus-1 as well as hepatitis C virus (HCV) are perhaps the most popular instances of persistent RNA viruses that cause chronic disease, proof recommends that numerous other RNA viruses, consisting of re-emerging viruses such as Ebola virus and Zika virus, develop persistent infections [2] . Furthermore, swine and avian influenza infections, together with Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), stand for substantial pandemic risks to the general populace [3] .

Considering the high frequency and vast circulation of RNA viruses, their huge genetic diversity as well as the frequent recombination of their genomes and raising activity at the human-animal interface, these viruses are identified as a recurring hazard to human health and wellness [4] . This truth once again became noticeably obvious in late 2019 and very early 2020, when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was found to be the root cause of a large and quickly spreading outbreak of lower respiratory tract infection and disease, consisting of potentially fatal pneumonia, in Wuhan, China [5, 6] . This novel coronavirus-induced febrile respiratory system disease was formally named coronavirus disease 2019 J o u r n a l P r e -p r o o f by the WHO. Presently, the COVID-19 pandemic is still spreading worldwide. Along with vaccinations, people are also hoping for particular medicines [7, 8] . An increasing number of medication prospects have come to the attention of clinical scientists, and many clinical trials are being performed throughout the world.

However, there is currently only one RNA-dependent RNA polymerase (RdRp) small molecule inhibitor, remdesivir, that has been approved by the United States Food and Drug Administration (FDA) for the treatment of COVID-19 [9] [10] [11] [12] .

An RNA virus is a virus that utilizes RNA as its genetic material. Based on their genome and mode of replication, three distinct groups of RNA viruses have been classified: double-stranded RNA viruses (dsRNA), single-stranded RNA (ssRNA) and

retroviruses [13, 14] . dsRNA viruses contain one to a dozen different RNA molecules, each of which encodes one or more viral proteins [15] . The genome of positive-sense ssRNA viruses is directly used as mRNA, and the host ribosomes translate this genome into a single protein that is modified by host and viral proteins to form the various proteins needed for replication [16] [17] [18] . One of these includes RdRp, which copies the viral RNA to develop a double-stranded replicative type [19, 20] .

Consequently, this dsRNA routes the development of brand-new viral RNA. The genome of negative-sense ssRNA viruses must be copied by an RNA replicase to form positive-sense RNA [21, 22] . The positive-sense RNA molecule then acts as viral mRNA, and this mRNA is translated into proteins by host ribosomes. In addition, retroviruses have a ssRNA genome but are generally not considered RNA viruses J o u r n a l P r e -p r o o f because they utilize DNA intermediates for replication [23] . The nucleic acid of a pathogenic virus, such as coronaviruses, hepacivirus, influenza viruses and respiratory syncytial virus (RSV), is typically ssRNA ( Table 1 ) [24, 25] . These RNA viruses can create lower respiratory system tract infections that cause bronchiolitis as well as pneumonia [26] . Young children, the elderly, and patients with compromised heart, lung, or immune systems are at the highest risk for significant disease related to these RNA virus-related breathing infections [27, 28] . Table 1 SARS-CoV-2 is a positive-sense ssRNA virus that can infect humans [29] . The infection largely spreads from human to human through close contact and by breathing droplets generated from sneezes or coughs. The 30-kb genome of SARS-CoV-2 contains 14 open reading frames (ORFs) that can encode at least 27 proteins [30] [31] [32] . The 3' end of the genome encodes four structural proteins, namely, spike, envelope, membrane, and nucleocapsid proteins, and eight accessory proteins that disrupt the host's inherent immune responses. The ORF1ab region at the 5' end inscribes a polyprotein, which is hydrolysed into 16 nonstructural proteins (nsp1- 16) to create a replicase/transcriptase complex (RTC). The main RTC is RdRp (nsp12) ( Fig. 1) . In RNA viruses, such as SARS-CoV-2, RdRp creates the machinery needed for RNA synthesis and the organized replication and transcription of genomic RNA. 

The genomic replication process of RNA infections is controlled by RdRp, which J o u r n a l P r e -p r o o f is inscribed by the virus itself [30, 33] . After the virus attacks a host cell, the viral genomic RNA is directly utilized as a template, and the host cell protein synthesis system is utilized for the translation of RdRp. RdRp is consequently used to complete the transcriptional synthesis of negative-strand subgenomic RNA, the synthesis of different structural protein-related mRNAs, and the replication of viral genomic RNA.

RdRp can properly and efficiently synthesize tens of thousands of nucleotides and thus facilitates all other biological activities that occur after the virus invades a host cell.

The structure of RdRp of positive-strand RNA viruses resembles that of a cupped right hand and includes fingers, palm and thumb subdomains that are largely associated with binding to the design template, polymerization, nucleoside triphosphate (NTP) access and associated features [34] [35] [36] . In addition to these three central subdomains, an N-terminal subdomain that bridges the fingers and thumb subdomains is located in all RdRps [37] , and this subdomain serves as the active site of RdRp. The completely encircled active site cavity is responsible for considerable communication between the finger and thumb subdomains. The active site of RdRp is extremely well preserved. The finger subdomain plays a considerable role in establishing the geometry of the active site [38] by holding the template RNA in place and facilitating polymerization. The thumb subdomain harbours residues that are involved in packing against the template RNA and stabilizing the initiating NTP on the template [39] . This subdomain also facilitates the translocation of the template following polymerization by accommodating large conformational rearrangements.

The thumb subdomain exhibits the greatest diversity among the identified RdRp and differences in size and complexity based on the mode of replication initiation. The palm subdomain translocates to the junction of the finger and thumb subdomains and houses many structurally conserved elements associated with catalysis [40] . The palm subdomain is involved in the selection of NTP over deoxyribonucleoside triphosphate (dNTP) and catalyses the phosphoryl transfer reaction by coordinating with two metal ions (Mg 2+ and/or Mn 2+ ). The best-known RdRps of positive-strand RNA viruses are the polioviral 3Dpol and hepatitis C virus nonstructural 5B (NS5B) proteins as well as the SARS-CoV-2 RdRp, which has recently attracted much attention.

The structure of the SARS-CoV-2 RdRp complex consists of a nsp12 core catalytic unit, a nsp7-nsp8 (nsp8-1) heterodimer, and an additional nsp8 subunit (nsp8-2), and nsp12-nsp7-nsp8 is defined as the minimal core component for virus RNA replication [31] . The N-terminal portion of nsp12 contains a b-hairpin (V31-K50) and a nidovirus-specific extension domain (D60-R249 

NIs terminate the RNA synthesis step, which is essential for RNA replication, through their incorporation by RdRp, which prevents incoming nucleotides from being added to the RNA chain [50] . It has been proposed that steric hindrance by nucleoside inhibitors, which contain a 3'-hydroxyl group, is responsible for the observed termination of chain elongation [51] . Due to this mechanism, NIs are sometimes called chain termination inhibitors [52] . NIs of RNA viruses, which have been developed as prodrugs, eventually become cleaved at their site of action in the liver by hepatic enzymes and undergo phosphorylation into a triphosphate form, which targets the polymerase at its highly conserved active site. NIs of RdRp are classified into three major classes: pyrimidine nucleoside inhibitors, purine nucleoside inhibitors and miscellaneous nucleoside inhibitors ( Table 2) . Unfortunately, clinical phase I trials showed that 9 does not have good pharmacokinetic characteristics. The low oral bioavailability of 9 might be due to the presence of hydroxyl and amino groups, which are more polar, exhibit poor fat solubility, and cannot easily penetrate biofilms in its structure [72] . In addition, its J o u r n a l P r e -p r o o f amino group at position 4 is unstable under acidic conditions, and this amino group can be easily removed to generate carbonyl groups. To resolve the problem of bioavailability and metabolism, the 3',5'-diisobutyrate prodrug 10 (mericitabine, RG-7128) was designed to promote the absorption and metabolism of the compound in the intestine [73] [74] [75] [76] . 10 is rapidly absorbed via the oral route and converted to 9,

which is subsequently metabolized to its metabolite. The results also showed that 10

improves the pharmacokinetic parameters, and clinical trials have also shown that the drug exerts a certain effect. However, 10 is not the most ideal medicine due to its low general efficacy and short t 1/2 .

in vivo [77] that can significantly inhibit HCV replication. The patients with hepatitis C treated with 11 generally show good tolerance. However, the bioavailability of 11 is too low (25%) because 11 cannot be converted into 11-triphosphate (11-TP). However, observations of the metabolites of 9 revealed that monophosphate 9 can be further transformed into 11-TP, which has a long t 1/2 and better activity than 9-TP [77, 78].

This major discovery indicates that uridine monophosphate derivatives might be ideal direct-acting antiviral agents (DAAs). To ensure the safety and efficiency of the drug, the F atom and methyl group at the C2' position are retained. Because compounds containing phosphoric acid groups are negatively charged, the related compounds cannot be easily absorbed by the human body. The prodrug design was finally adopted, and the first prodrug 12 (PSI-7672) was designed [77] . Since then, a large number of J o u r n a l P r e -p r o o f derivatives have been synthesized, and some of the related experience has been previously summarized [79] . The isomeric form of the amino acid is significant because the D-alanine derivative is inactive, which means that the natural L-amino acid is required for activity. Observations of the amino acid side chain (R 1 ) have revealed that a small alkyl group is a viable substitution, but significant decreases in potency are observed with substitutions larger than ethyl. Methyl results in the greatest potency and is therefore a viable substitution. If the amino acid is alanine and the phosphate ester is a phenyl substituent, the groups at the carboxylic acid ester (R 2 ) that provide the desired submicromolar activity are small alkyl groups and branched alkyl groups. However, cytotoxicity was observed with n-butyl, 2-butyl and n-pentyl esters. Phenyl and halogenated alkyl groups do not provide sufficient improvements in potency. The evaluation of the phosphoramidate ester substituent (R 3 ) revealed that a derivative with phenyl as a substituent exhibits good potency and is not cytotoxic ( Table 3) .

It was finally determined that 13 (PSI-7851) is an ideal DAA with a favourable profiles and decreased production of toxic metabolites that could yield improvements in efficacy, tolerability, or safety [96] . Therefore, 19 is well tolerated and induces no serious adverse events in healthy volunteers and hepatitis C patients [97] . Among active patients, increasing doses of 19 resulted in increased viral decline. In the proof of concept group administered 700 mg of the antiviral, mean decreases in the maximum viral load of 3.4 log 10 , 4.2 log 10 , and 4.6 log 10 were obtained after 7, 10, and 14 days of treatment, respectively. Three of six patients (50%) achieved viral clearance after the administration of 700 mg for 14 days.

20 (galidesivir, BCX4430) is an adenosine nucleoside analogue developed by BioCryst Pharmaceuticals. This compound was originally intended as a treatment for HCV but was subsequently developed as a potential treatment for deadly filovirus infections [98, 99] . Studies have shown that 20 protects against both Ebola and Marburg viruses in both rodents and monkeys [99] . This compound also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, [123] . In addition, a clinical trial studied the efficacy and safety of the combination of interferon beta-1b, lopinavir-ritonavir, and 27 for the treatment of patients with COVID-19. The results showed that early triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the durations of viral shedding and hospital stay in patients with mild symptoms, and the side effects were mild and controllable [124] . However, the results from the trial need to be further verified by an expanded double-blind trial. It is worth noting that the safety of ribavirin has been controversial. The adverse reactions that have been reported include teratogenicity and haemolytic anaemia [125] . have been discovered [129, 130] . Two of these sites are located in the thumb subdomain of the polymerase, and the other three are located in the palm subdomain.

The NNIs of HCV can be divided into five different classes according to the location of their respective binding sites (referred to as thumbs I and II and palms I, II and III) ( Table 4 ). Table 4 3 increasing dose [135] . However, at high doses (450 mg), all five actively treated patients were unable to tolerate the compound due to gastrointestinal reactions, and clinical studies have been discontinued [136] .

Whether the compound has benzimidazole or indole as its core, the dihedral angle between the core and the 2-position aryl group exerts a greater impact on the activity of the compound during the process of structural modification [137] . [141] . However, the use of 35 for the treatment of hepatitis C has been discontinued by Boehringer Ingelheim due to weak market competition. 36 (beclabuvir, BMS-791325) is a thumb Ⅰ-NS5B polymerase ligand [142] . In cell culture, 36 inhibits the replication of HCV subgenomic replicons representing HCV GTs 1a and 1b at EC 50 values of 3 nM and 6 nM, respectively, and similar values (3 to 18 nM) were obtained for GTs 3a, 4a, and 5a [143] . The oral bioavailability of 36 is 66%, and its volume of distribution is 2.7 L/kg; following intravenous administration, a plasma clearance of 3.5 mL/min/kg and an estimated plasma t 1/2 of 8.3 h were obtained in a 24-h rat pharmacokinetic study [144] . 36

represents a valid drug that exhibits a good tolerability and safety profile, and together with other antivirals, this compound exhibits optimal efficacy against HCV in compensated phases of the diseases, as demonstrated in clinical studies [145, 146] . At present, 36 in combination with asunaprevir and daclatasvir has been launched in Japan for the treatment of hepatitis C.

The thumb II site is a spatially distinct allosteric site on the polymerase situated at the base of the thumb subdomain at a distance of 30 Å from the enzyme active site.

Inhibitors acting on the thumb II site are mainly dihydropyrones, thiophene carboxylic acids and pyranoindole compounds. The lipophilic substituents of these compounds occupy the shallow grooves formed by the amino acid residues Leu419, Tyr477 and Trp528 in the thumb Ⅰ site. The acidic groups of the compounds generate hydrogen bonds with the backbone amide bonds of the amino acid residues Ser476 and Tyr477 [147, 148] . respectively [154] . In a phase I clinical trial of 41, the average viral load of HCV type 1 patients who were treated with 800 mg TID was evaluated 10 days later, and the largest decrease in volume reached 2.5 log 10 IU/mL [155] . Although more patients had diarrhoea, no serious adverse reactions were observed. The EC 50 value of 42 for HCV J o u r n a l P r e -p r o o f GT 1 in the replicon model was found to be equal to 0.1 µM [156] . In a clinical phase I trial, the compound rapidly reduced the viral load of HCV GT 1 patients after 3 days of treatment, and the maximum reduction in viral load obtained with these treatments was 1.5 log 10 IU/mL [157] . The compound was well tolerated in healthy volunteers administered a single oral dose of 1500 mg and in patients with HCV orally administered 750 mg BID, and the maximum average viral load observed 3 days after the treatment was decreased by 3.7 log 10 IU/mL. The phase II clinical trial of 43 in combination with telaprevir for the treatment of patients with HCV GT 1 was terminated [158, 159] .

Compound 44 (HCV-371) is a type of pyranoindole HCV thumb Ⅰ inhibitor that has a structure that differs from that of the two abovementioned types of compounds [160] [161] [162] . For 90% HCV GTs 1a and 1b, the IC 50 value was 0.3~1.4 µM, the IC 50 value for HCV GT3a inhibition was 1.8 µM, and the EC 50 values for HCV GTs 1a and 1b in the replicon model were 6.1 and 4.8 µM, respectively. The compound was well tolerated in clinical phase I trials, but due to a lack of significant antiviral activity, clinical trials of the compound have been terminated.

The palm I binding site is located between the active site and the palm II site and contains a deep hydrophobic pocket. The inhibitors that bind to this site mainly include N-aryl uracil analogues, benzothiadiazines and acyl pyrrolidines.

A series of N-aryl uracil analogues was reported as a novel structural class of NS5B polymerase NNIs [163] . CYP450 inhibition, or off-target or drug-drug interactions [177] . In the phase Ⅰ study, a rapid and marked decline in HCV RNA levels, slow viral rebound after treatment, and no viral breakthrough during treatment were observed in the patients, which

indicates that this compound is highly favourable compared with the currently approved NNIs [178] .

The palm II site is mainly composed of a large hydrophobic pocket in the palm area, and the RdRp inhibitors that bind to this site include benzofurans. These palm II site inhibitors are different from other nonnucleoside inhibitors in that they exhibit potent activity against HCV GTs 1 to 4 and NS5B polymerase. 

Cliff C. Cheng et al. [184] described a novel series of NS5B polymerase inhibitors based on the 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamide-based scaffold.

Among them, the first palm III inhibitor identified was 54, and its IC 50 value related to the inhibition of HCV GT 1b NS5B polymerase was 0.8 µM. The X-ray crystal structure of a complex with 54 has provided structural insights into the mechanism of inhibition and aided the rationalization of the structure-activity relationships. replaced the hydrogen in the active molecular group with isotope deuterium to close the metabolic site and prolong the t 1/2 of the drug, which further improves the metabolism of remdesivir in vivo and expands the scope of the treatment window and thereby reduces the therapeutic dose [190] . Additionally, the pharmacophore model is a ligand-based drug design tool that starts from the structure of known active compounds to find common pharmacodynamic feature information, thereby guiding the rational design or virtual screening of new compounds. M.S.A. Parvez et al. [187] designed a pharmacophore using 22, which was used further for screening the ZINC database. Molecular docking analysis revealed that two compounds (ZINC09128258 and ZINC09883305) with pharmacophore features that interact effectively with RdRp of SARS-CoV-2, indicating their potential as effective inhibitors of the enzyme (Fig.   9 ). In addition, in recent years, the research and development of RdRp inhibitors for RNA viruses has continued to be hot. Wang et al. reported the synthesis and biological evaluation of a series of 2',3'-and 2',4'-substituted guanosine nucleotide analogues as HCV NS5B polymerase inhibitors [191] . 6'-Fluorinated aristeromycins were designed as dual-target antiviral compounds for the development of broad-spectrum antiviral agents that target RNA viruses [192] . These new compounds may also be a J o u r n a l P r e -p r o o f hope against the COVID-19 epidemic.

Undeniably J o u r n a l P r e -p r o o f 

Persistent RNA virus infections: do PAMPS drive chronic disease?, Current Opinion in Virology

Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses

Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review

Zika… what next?

Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances

COVID-19 vaccine trials should seek worthwhile efficacy

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Evolution of RNA viruses

Parallels among positive-strand RNA viruses, reverse-transcribing viruses and double-stranded RNA viruses

Conservative transcription in three steps visualized in a double-stranded RNA virus

Host factors in positive-strand RNA virus genome replication

Packaging of Genomic RNA in Positive-Sense Single-Stranded RNA Viruses: A Complex Story

The relationship between mutation frequency and replication strategy in positive-sense single-stranded RNA viruses

An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA

Insights from Structure, Function and Evolution

Nonsegmented Negative-Sense RNA Viruses-Structural Data Bring New Insights Into Nucleocapsid Assembly

Retroviral Vectors in Gene Therapy, eLS

Evolution and Emergence of Pathogenic Viruses: Past

Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study

RNA Roles in Pathogenesis, Coreplication and Viral Load

Influenza A Virus Infection Causes Chronic Lung Disease Linked to Sites of Active Viral RNA Remnants

Respiratory viral diseases: access to RNA interference therapy

RNA polymerase as target for antiviral therapy

Structure of replicating SARS-CoV-2 polymerase

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from

RNA virus replication, transcription and recombination

Origin and Evolution of RNA-Dependent RNA Polymerase

RNA dependent RNA polymerases: insights from structure, function and evolution

Structure of the RNA-dependent RNA polymerase of poliovirus

Characterization of the N-terminal domain of classical swine fever virus RNA-dependent RNA polymerase

Phosphorylation at the N-terminal finger subdomain of a viral RNA-dependent RNA polymerase

Common and unique features of viral RNA-dependent polymerases

RNA-Dependent RNA Polymerases of J o u r n a l P r e -p r o o f Picornaviruses: From the Structure to Regulatory Mechanisms

Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses

The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase

Structural basis of an essential interaction between influenza polymerase and Pol II CTD

Crystal structure of the RNA-dependent RNA polymerase from influenza C virus

Molecular mechanisms of transcription and replication of the influenza A virus genome

Cryo-EM the respiratory syncytial virus RNA polymerase

Structure of the L Protein of Vesicular Stomatitis Virus from Electron Cryomicroscopy

Recombinant RNA-dependent RNA polymerase complex of Ebola virus

Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir

Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase

Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides

Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase

Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Small-Molecule Antiviral beta-D-N-4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

beta-D-N-4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome

Viral polymerases, Viral Molecular Machines

Nucleoside analogue 2'-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin

Characterization of the activity of 2'-C-methylcytidine against dengue virus replication

Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine

Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-fluoro-4'-chloromethyl-cytidine triphosphate

Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase

Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection

Discovery of 4′-chloromethyl-2′-deoxy-3′

ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection

Discovery of 4′-azido-2′-deoxy-2′-C-methyl cytidine and prodrugs thereof: A potent inhibitor of

Hepatitis C virus replication

Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication

Mechanism of activation of β-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase

Inhibition of hepatitis C virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase

Sofosbuvir protects Zika virus-infected mice from mortality, preventing short-and long-term sequelae

Zika Virus Disrupts Phospho-TBK1

Localization and Mitosis in Human Neuroepithelial Stem Cells and Radial Glia

Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication<sup/>

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B

Sofosbuvir protects human brain organoids against SARS-CoV-2, bioRxiv

Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′-C-methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

JNJⅠ4178 (ALⅠ335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C VirusⅠInfected Patients Without Cirrhosis: OMEGAⅠ1

Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro

Triphosphate Useful for HCV Inhibition

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus

ALS-2200, a novel once-daily nucleotide hcv polymerase inhibitor, demonstrated potent antiviral activity in treatment-nave patients with compensated cirrhosis or genotype 2-4 chronic hepatitis c

Deuterium isotope effects in studies of drug metabolism

LP27: ACH-3422, A novel nucleotide prodrug inhibitor of HCV NS5B polymerase

Potent Inhibition of the C-P Lyase Nucleosidase PhnI by Immucillin-A Triphosphate

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430

Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters

Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis

The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies

The ProTide Prodrug Technology: Where Next?

A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19

Remdesivir for the Treatment of Covid-19 -Final Report

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment

Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis

Chutes and ladders in hepatitis C nucleoside drug development

Potent antiviral activity of second generation nucleoside inhibitors, IDX102 and IDX184, in HCV-infected chimpanzees

Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) in treatment -naive HCV genotype 1-infected subjects

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

Ebola virus dynamics in mice treated with favipiravir

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering (Beijing), (2020)

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection

Ribavirin: pharmacology, multiple modes of action and possible future perspectives

Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo

Ribavirin in the treatment of severe acute respiratory syndrome (SARS)

Ribavirin therapy for severe COVID-19: a retrospective cohort study

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: centers

Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial

Advances in respiratory virus therapeutics -A meeting report from the 6th isirv Antiviral Group conference

Selection and characterization of replicon variants dually resistant to thumb-and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus

Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives

Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate

Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109

Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells

Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds

AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization

Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase

benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C J o u r n a l P r e -p r o o f virus NS5B polymerase

Safety and Antiviral Activity of NS5B

Polymerase Inhibitor MK-3281

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis

Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme

Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase

Beclabuvir for the treatment of hepatitis C

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection

A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B

Crystal structures and mechanism of inhibition

The crystal structure of the RNA-dependent RNA polymerase from human rhinovirus: a dual function target for common cold antiviral therapy

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase

GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection

Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase

Discovery of (R)-6-cyclopentyl-6

pyrimidin-2-yl) methyl)-4-hydroxy-5, 6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication

Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors

Evaluation of VCH-759 monotherapy in hepatitis C infection

Results of a safety, tolerability and pharmacokinetic phase I study of VCH-916, a novel polymerase inhibitor for HCV, following single ascending doses in healthy volunteers

Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir, Antimicrobial Agents and

935 identification and characterization of VCH-222, a novel potent and selective non-nucleoside HCV polymerase inhibitor

Safety, toperability and pharmacokinetics of the HCV polymerase inhibitor VCH-222

following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals

Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors

Design and synthesis of 2,3,4,9-tetrahydro-1H-carbazole and 1,2,3,4-tetrahydro-cyclopenta[b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase

Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase

Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B

Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability

Synthesis and biological characterization of aryl uracil inhibitors of hepatitis C virus NS5B polymerase: discovery of ABT-072, a trans-Stilbene analog with good oral bioavailability

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals

C/C patients with chronic hepatitis C genotype 1

Identification of aryl dihydrouracil derivatives as palm initiation site inhibitors of HCV NS5B polymerase

In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor

Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection

Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase

,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase

1055 ANTIVIRAL ACTIVITY OF ANA598, A POTENT NON-NUCLEOSIDE POLYMERASE INHIBITOR

12-week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon + ribavirin, following 3-day monotherapy in genotype 1 HCV infected treatment-naive subjects

Jarvest, GSK625433; a novel and highly potent inhibitor of the HCV NS5B polymerase

vitro activity and pharmacological properties of IDX375, a novel HCV non-nucleoside inhibitor

First-in-human study of the pharmacokinetics and antiviral activity of IDX375, a novel nonnucleoside hepatitis C virus polymerase inhibitor

CC-31244, A Novel, Pan-Genotypic, Potent NS5B Non-Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C

Phase 1 study assessing the safety, pharmacokinetics, and antiviral activity of CC-31244, a pan-genotypic, potent non-nucleoside NS5B polymerase inhibitor for the treatment of hepatitis C virus infection

Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor

Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCVNS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects

Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a

Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides

Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Effect of quantum nuclear motion on hydrogen bonding

Deuterium A nucleoside analogue and preparation method and use thereof

Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C

Virus Activity of 6′-Fluorinated-Aristeromycin Analogues